Modeling the effectiveness of nebulized terbutaline for decompensated chronic obstructive pulmonary disease patients in the emergency department
- PMID: 27512880
- PMCID: PMC4985335
- DOI: 10.1097/MD.0000000000004553
Modeling the effectiveness of nebulized terbutaline for decompensated chronic obstructive pulmonary disease patients in the emergency department
Abstract
Short-acting β2-agonists (SABA) are widely used in the emergency department (ED) to treat patients with decompensated chronic obstructive pulmonary disease (COPD). We sought to model the effectiveness of nebulized SABA (terbutaline) on clinically relevant parameters associated with a reduction in work of breathing or respiratory muscle fatigue in decompensated COPD patients admitted to the ED.Forty consecutive decompensated COPD patients (having received at least one dose of nebulized terbutaline during their stay in the ED) were included in an observational cohort study. The terbutaline dose received at time t was expressed as cumulative dose and as a rate (mg/day). The associations between the terbutaline dose and time-dependent outcome parameters (respiratory rate, heart rate, arterial blood gases, and, as a marker of terbutaline's systemic effect, serum potassium) were analyzed using a nonlinear, mixed-effects model. The effect of various covariates influencing terbutaline's effectiveness (baseline characteristics and concomitant treatments) was assessed on the model.Among the investigated patients, a total of 377 time-dependent observations were available for analysis. Neither the cumulative dose nor the dose rate at time t significantly influenced the arterial blood gas parameters or heart rate. The cumulative dose of terbutaline was associated with a lower serum potassium level (P < 0.001) and, less significantly, a lower respiratory frequency (P = 0.036). In a tertile analysis, the need for post-ED hospitalization was not associated with the cumulative dose or dose rate of terbutaline.Overall, the results of our modeling study strongly suggest that terbutaline dose did not influence time-dependent outcomes other than serum potassium, and thus call into question the systematic administration of inhaled SABA to patients admitted to the ED for decompensated COPD.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures


Similar articles
-
Nebulized Terbutaline and Ipratropium Bromide Versus Terbutaline Alone in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Requiring Noninvasive Ventilation: A Randomized Double-blind Controlled Trial.Acad Emerg Med. 2019 Apr;26(4):434-442. doi: 10.1111/acem.13560. Epub 2018 Oct 21. Acad Emerg Med. 2019. PMID: 30156361 Clinical Trial.
-
Reduction in Hospital Readmission Rates Among Medicare Beneficiaries With Chronic Obstructive Pulmonary Disease: A Real-world Outcomes Study of Nebulized Bronchodilators.Clin Ther. 2019 Nov;41(11):2283-2296. doi: 10.1016/j.clinthera.2019.09.001. Epub 2019 Oct 17. Clin Ther. 2019. PMID: 31630815
-
Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.Clin Ther. 2010 Jul;32(7):1320-8. doi: 10.1016/j.clinthera.2010.06.022. Clin Ther. 2010. PMID: 20678680
-
Use of inhaled devices during a hospital exacerbation of COPD: a summary of an interdisciplinary audit held at ICS Maugeri Pavia, Italy (March-June 2019).Monaldi Arch Chest Dis. 2020 Feb 12;90(1). doi: 10.4081/monaldi.2020.1176. Monaldi Arch Chest Dis. 2020. PMID: 32072800
-
A review of nebulized drug delivery in COPD.Int J Chron Obstruct Pulmon Dis. 2016 Oct 18;11:2585-2596. doi: 10.2147/COPD.S114034. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27799757 Free PMC article. Review.
Cited by
-
Effect of terbutaline plus doxofylline on chronic obstructive pulmonary disease.Am J Transl Res. 2021 Jun 15;13(6):6959-6965. eCollection 2021. Am J Transl Res. 2021. PMID: 34306449 Free PMC article.
-
Clinical efficacy of glucocorticoid and terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Am J Transl Res. 2021 Jun 15;13(6):7029-7034. eCollection 2021. Am J Transl Res. 2021. PMID: 34306459 Free PMC article.
References
-
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2015. Available at: http://www.goldcopd.org Accessed October 21, 2015.
-
- Philipson LH. β-Agonists and metabolism. J Allergy Clin Immunol 2002; 110:S313–S317. - PubMed
-
- Faisy C, Pinto F, Danel C, et al. Modulation of CD8+ T and B-cells chemotaxis by β2-adrenoceptor agonist in isolated COPD airways. Pharmacol Res 2010; 61:121–128. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous